Celecoxib Supply in 2026: A Prescriber's Perspective

Celecoxib remains one of the most widely prescribed NSAIDs in the United States, valued for its selective COX-2 inhibition and significantly lower gastrointestinal risk compared to nonselective NSAIDs. While Celecoxib is not currently on the FDA Drug Shortage list, many clinicians are fielding calls from patients unable to fill prescriptions at their usual pharmacies.

This guide provides an overview of the current Celecoxib supply landscape, evidence-based therapeutic substitution options, and practical strategies for minimizing disruptions to patient care.

Current Availability Status

As of March 2026:

• No official shortage: Celecoxib is not listed on the FDA Drug Shortage database or the ASHP current shortage list.
• Localized spot shortages: Patients may encounter temporary stock-outs at individual pharmacies, particularly for the 200 mg capsule strength.
• Multiple generic manufacturers: Teva, Mylan (Viatris), Aurobindo, Dr. Reddy's, and several other generic manufacturers continue to produce Celecoxib capsules in all strengths (50 mg, 100 mg, 200 mg, 400 mg).
• Brand Celebrex: Pfizer continues to manufacture brand-name Celebrex, though it is rarely stocked by retail pharmacies due to the wide availability of generics.

Understanding the Supply Chain Factors

Several factors contribute to the intermittent availability issues clinicians may be hearing about from patients:

Distributor-Level Dynamics

The three major U.S. drug distributors (McKesson, AmerisourceBergen/Cencora, and Cardinal Health) manage the flow of generics from manufacturers to pharmacies. Allocation limits, inventory management algorithms, and contractual arrangements can create pockets of unavailability even when national supply is adequate. Pharmacies locked into a single-source contract may be disproportionately affected if their contracted manufacturer experiences any production variability.

Manufacturer Production Variability

Generic pharmaceutical manufacturing operates on thin margins. Production schedule adjustments, quality control holds, API sourcing delays, and facility maintenance can all temporarily reduce output from individual manufacturers. With multiple producers in the market, these disruptions are typically absorbed at the national level but can create noticeable gaps at the pharmacy level.

Demand Fluctuations

Insurance formulary changes, seasonal prescribing patterns, and clinical guideline updates can all influence Celecoxib demand. A shift toward Celecoxib as a first-line NSAID recommendation in patients with GI risk factors has contributed to steady demand growth.

Clinical Considerations for Therapeutic Substitution

When patients cannot access Celecoxib and require a therapeutic alternative, consider the following evidence-based options:

Meloxicam (7.5-15 mg daily)

• Clinical rationale: Preferential COX-2 selectivity, though less selective than Celecoxib. The PRECISION trial established cardiovascular non-inferiority of Celecoxib vs. Naproxen and Ibuprofen, but Meloxicam was not included. Observational data suggest a similar CV safety profile.
• GI safety: Better than nonselective NSAIDs but possibly higher GI risk than Celecoxib based on limited head-to-head data.
• Availability: Widely available, extremely affordable ($4-$10/month generic).
• Dosing: Once daily, which may improve adherence for patients accustomed to once-daily Celecoxib dosing.

Naproxen (250-500 mg BID)

• Clinical rationale: The AHA has historically suggested Naproxen may have the most favorable CV risk profile among NSAIDs, though the PRECISION trial found Celecoxib non-inferior. Good option for patients with higher CV risk.
• GI safety: Higher GI event rates than Celecoxib. Consider co-prescribing a PPI (Omeprazole, Esomeprazole) in patients with GI risk factors.
• Availability: Available OTC and by prescription. Very affordable.

Diclofenac (50 mg BID-TID or topical gel)

• Clinical rationale: Effective analgesic and anti-inflammatory. Topical Diclofenac gel (1%) is FDA-approved for OA of joints amenable to topical treatment and provides localized relief with minimal systemic absorption.
• GI safety: Oral Diclofenac carries GI risk comparable to other nonselective NSAIDs. Topical route significantly reduces GI exposure.
• Availability: Oral generic widely available. Topical Voltaren Arthritis Pain is OTC.

Non-NSAID Alternatives

For patients in whom all NSAIDs are problematic:

• Duloxetine (60 mg daily): FDA-approved for chronic musculoskeletal pain and OA. Consider for patients with comorbid depression or anxiety.
• Acetaminophen (up to 3,000 mg/day): Modest efficacy for OA but avoids GI, CV, and renal risks of NSAIDs.
• Topical capsaicin or lidocaine patches: Adjunctive options for localized pain.
• Intra-articular corticosteroid injections: For acute flares of OA or inflammatory arthritis.

Helping Patients Find Celecoxib

Before switching therapy, consider helping patients locate Celecoxib at another pharmacy. Many spot shortages are geographically limited, and the medication may be available at a nearby location.

• MedFinder for Providers enables you to direct patients to pharmacies with verified stock. Share the link with your clinical staff for integration into patient communication workflows.
• Recommend patients try multiple pharmacy chains — different chains use different distributors and may have stock from different generic manufacturers.
• Consider prescribing 100 mg capsules (two capsules instead of one 200 mg capsule) as a temporary workaround if the 200 mg strength is unavailable.
• Mail-order pharmacies may have more consistent supply for maintenance prescriptions.

Documentation and Communication

When managing patients affected by Celecoxib availability issues:

• Document the reason for any therapeutic substitution in the patient's chart.
• If switching to a nonselective NSAID, assess and document GI risk factors and consider gastroprotective co-therapy.
• Communicate with the patient's pharmacy to understand expected timelines for resupply.
• Schedule follow-up to reassess if a temporary substitution has been made.

Monitoring Official Shortage Channels

Stay informed through these resources:

• FDA Drug Shortage Database
• ASHP Drug Shortage Resource Center
• MedFinder Provider Tools — real-time pharmacy stock visibility

For patient-facing resources to share, see our Celecoxib shortage update for patients and how to find Celecoxib in stock.

Key Takeaways for Providers

• No official national shortage of Celecoxib exists as of March 2026, but localized pharmacy stock-outs are occurring.
• Meloxicam is the most pharmacologically similar alternative; Naproxen may be preferred for higher CV-risk patients.
• Consider co-prescribing a PPI when switching patients to nonselective NSAIDs.
• Direct patients to MedFinder to check pharmacy availability before scheduling office visits or making therapy changes.
• Document therapeutic substitutions and plan for reassessment when Celecoxib becomes available to the patient.